Clinical Trials Logo

Filter by:
  • Recruiting  
  • Page [1] ·  Next »
NCT ID: NCT06368908 Recruiting - Clinical trials for Critical Illness Myopathy

Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill

FMS_ICU
Start date: December 8, 2023
Phase: N/A
Study type: Interventional

ICU-Acquired weakness (ICU-AW) is a significant complication of critical illness. ICU-AW is common in patients with sepsis, systemic inflammatory response, and mechanically ventilated. It is estimated that around 50% of patients recovering from the primary illness remain in intensive care with characteristic muscle weakness. This leads to dependence on mechanical ventilation, prolonging costly intensive care hospitalization. The myopathy causes persistent functional impairment, endangering patients long after hospital discharge. Magnetic stimulation prevents inactivation atrophy of skeletal muscles, as demonstrated in the mobilized limb of rats. Transcutaneous magnetic stimulation of the quadriceps via the femoral nerve is a safe and painless method even when applied to humans. In patients with chronic obstructive pulmonary disease (COPD), quadriceps magnetic stimulation increased spontaneous contraction force compared to the control group and improved quality of life. Patients with COPD tolerate quadriceps magnetic stimulation well, as it does not affect oxidative stress in muscles but does increase the size of slow-twitch muscle fibers. In intensive care medicine, magnetic stimulation has been primarily used for diagnostic purposes in assessing diaphragm function, peripheral muscle strength assessment, and transcranial electrical stimulation as a diagnostic tool and therapeutic stimulation of brain cells. With the development of modern transcutaneous magnetic stimulators, the possibility arises for their use in intensive care medicine for therapeutic purposes such as preventing critical illness myopathy. To date, no research has been conducted on the use and effectiveness of magnetic stimulation of peripheral muscles in critically ill individuals. The aim of the study is to investigate the effect of Functional Muscle Magnetic Stimulation (FMS) on the development of ICU-AW.

NCT ID: NCT06365463 Recruiting - Ischemic Stroke Clinical Trials

Telerehabilitation to Improve Balance and Mobility in Patients After Stroke

TeleHome
Start date: April 9, 2024
Phase: N/A
Study type: Interventional

Telerehabilitation is an effective rehabilitation method that allows patients to receive physiotherapy remotely in their homes. The purpose of this study was to investigate the effects of home-based remote group training for balance and mobility on activities and body functions.

NCT ID: NCT06343610 Recruiting - Clinical trials for Minimal Erythema Dose

The Effect of 8-week Dietary Intake of Novel Food Supplement on Minimal Erythema Dose

VIST-TO-UV
Start date: April 2024
Phase: N/A
Study type: Interventional

This is a double-blind, randomized, placebo-controlled interventional study of the effect of multiple-dose dietary intake on minimal erythema dose and other skin parameters.

NCT ID: NCT06275204 Recruiting - Gastric Cancer Clinical Trials

H. Pylori Screen-and-treat Study in a Population of Young Adults

Start date: March 4, 2024
Phase:
Study type: Observational

Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe. Considering its absolute burden and persisting disparities, in addition to the substantial prevalence of H. pylori infection worldwide that is treatable, gastric cancer is a logical target for urgent action for prevention. Population-based H. pylori test-and-treat has therefore been proposed as a strategy for gastric cancer prevention. To fill the gaps in knowledge about gastric cancer prevention through H. pylori screening and eradication in younger adults, a study of a population-based H. pylori test-and-treat strategy in Ireland, Croatia, Latvia, Poland, Romania and Slovenia. Main goals of this study are to assess future program processes, feasibility, acceptability and effectiveness. In total of 6,800 adults aged 30-34 will be tested for H. pylori infection. They will be randomly selected to represent the chosen population and invited to participate in the study based on informed consent. Confirmed infections will be treated by available combined therapy in line with treatment guidelines and the success of eradication will be retested during a control check-up. Patients who will provide their consent to participate will undertake an interview about the risk factors in early childhood and their habits regarding alcohol consumption and use of tobacco. Compliance to testing and treatment, treatment results, adverse effects and reasons for dropping out will be additionally monitored. Gathered data will be analysed in alignment with our research questions. The investigators will disseminate reports and present the results to both the general public and the scientific community in order to foster future developments in gastric cancer prevention.

NCT ID: NCT06255171 Recruiting - Suicidal Behaviour Clinical Trials

Social Media and Suicidal Behaviour - Study 1

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

There is limited research investigating the correlation between suicidal behavior in the general population and online journalism reporting on suicide. Even less explored are the roles and characteristics of suicide-related news posts on social media platforms, along with reader comments, and their association with users' experiences. The primary objective of this randomized controlled trial is to experimentally examine the influence of these post features on user perceptions. Participants are expected to be university students or young adults. In line with this aim, the following research question has been posed: How do users of social media and forums perceive news posts about suicide on social media platforms? Participants will complete a screening battery of questionnaires. Those who will be eligible to participate will be divided into 1 experimental and 2 control groups. Firstly the participants will fill out a questionnaire regarding their current mood. Each group will read posts of a different theme, one of them will be suicidal behavior, deaths due to traffic accidents, and nature. They will be asked to observe and read 4 social media posts and their corresponding articles. After each article, they will answer a few questions on how they perceived these articles and how are they currently feeling. After the main part of the study, all groups of participants will be involved in a group debriefing conversation.

NCT ID: NCT06203704 Recruiting - Clinical trials for Chronic Kidney Disease (CKD)

Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients

OPTIMISE-CKD
Start date: December 20, 2023
Phase:
Study type: Observational

The OPTIMISE-CKD CEE study design will create a real-world evidence platform that systematically leverages the routine data collection made by Investigators and will help obtain relevant insights from clinical practice. This study is likely to include a more heterogeneous population compared with the constraints required by interventional study protocols. Treatment decisions, clinical outcomes, and common treatment scenarios in the context of routine care of CKD are likely to be more generalizable than those from clinical trials. It is important to assess the current CKD treatment with dapagliflozin. The research questions can be divided into two categories: 1. What does the dapagliflozin utilisation in CKD look like? a. Who are being treated? 2. What are the selected outcomes of interest and treatment patterns among CKD patients treated with dapagliflozin, with or without type 2 diabetes (T2D) up to 12 months post-initiation? Primary objective is to characterize dapagliflozin utilisation in clinical practice, by describing treatment naïve patients who are treated with dapagliflozin for CKD. Secondary objectives are to describe selected outcomes of interest and treatment patterns among CKD patients treated with dapagliflozin up to 12 months post-initiation. The OPTIMISE-CKD CEE study is a multinational, observational, longitudinal cohort study, with a pre-post design, which will include patients who are treated with dapagliflozin with CKD in real-world clinical practice, utilising secondary data sources. This is a secondary data collection study, where variables are extracted from electronic or paper medical records. Seven Central Eastern Europe countries are planned to participate in the study: Bulgaria, Croatia, Hungary, Poland, Romania, Serbia and Slovenia. A total number of 1090 patients are estimated to be included in the study. The study population will consist of adult patients with CKD who meet the country-specific label for dapagliflozin as treatment for CKD across CEE.

NCT ID: NCT06155812 Recruiting - Shock, Septic Clinical Trials

Multimodal Vasopressor Strategy in Septic Shock

Start date: November 3, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this prospective randomized controlled trial is to compare the effects of classic stepwise vs. early balanced multimodal vasopressor strategies in septic shock.

NCT ID: NCT06154044 Recruiting - Heart Failure Clinical Trials

Cell Therapy and Myocardial Recovery in Heart Failure Patients Undergoing Left Ventricular Assist Device Support

CELL-VAD
Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

The goal of CELL-VAD Pilot trial is to investigate a personalized stem cell therapy approach for patients with advanced non-ischemic chronic heart failure (NICM) who are supported by LVAD. In the clinical trial, the investigators aim to enroll 10 patients with NICM, scheduled for LVAD implantation. After successful LVAD implantation, patients will be enrolled and followed for 2 months to allow for postoperative rehabilitation and heart failure medical therapy and LVAD support optimization. All patients will then undergo autologous CD34+ cell therapy which will be intracoronaryly delivered to the target myocardium using NOGA electromechanical mapping system. All patients will be followed for 6 months after cell therapy. At baseline, and at 1, 3, and 6 months after cell therapy, the investigators will perform comprehensive clinical evaluation.

NCT ID: NCT06153160 Recruiting - Cardiac Arrest Clinical Trials

"The Effect of the Use of an Autotransfusion Device on Hemodynamic Parameters During Resuscitation".

Start date: November 22, 2023
Phase: N/A
Study type: Interventional

The purpose of the research (pilot study) is to determine the impact of the use of the autotransfusion device on hemodynamic parameters during resuscitation. 24 people will be included in the pilot study (12 people will be included in the intervention group - with the usage of "autotransfusion socks" during resuscitation and 12 people in the control group - without "autotransfusion socks"). Investigators will compare the hemodynamic parameters and also neurological outcome between both groups.

NCT ID: NCT06143124 Recruiting - Clinical trials for Helicobacter Pylori Infection

Bismuth Quadruple Therapy Versus Standard Triple Therapy

BismoHelP
Start date: March 3, 2022
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to compare the standard triple therapy with Bismuth quadruple therapy in children infected with Helicobacter pylori. The main questions to answer are: - the safety - the efficacy of the quadruple protocol with Bismuth subcitrate Participants will be randomised in 7-days eradication therapy group and 14-days eradication control group.